Traded May 28 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Apr 30, 2026 · Filed May 2, 2026
The CFO of United Therapeutics sold $1.74M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,735,457
Shares × reported transaction price
64 days after results of Feb 25, 2026, 6 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded May 28 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$180K of United Therapeutics
Scheduled in advanceJames Edgemond (CFO AND TREASURER) sold ~$1.1M of United Therapeutics
Scheduled in advance